Key facts
- Restore Medical’s last known valuation is $19.6M (Mar 2023).
- It has raised $30.4M; the latest was Later Stage VC ($23.0M) in Jul 2025.
- Notable investors include European Innovation Council, Pitango Venture Capital, Peregrine Ventures, Allegro Venture Partners, Edwards Lifesciences — 6 tracked in total.
- Restore Medical has filed 1 Form D with the SEC, most recently Oct 2014 ($50K sold to 3 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Restore Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for Restore Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Restore Medical
Developer of a medical device company designed to offer treatment for patients with congestive heart failure. The company offers catheter implants for patients with left ventricular failure that improve left ventricular ejection fraction, reduce mitral regurgitation, and restore favorable ventricular geometry, enabling patients to enhance quality of life and reduce hospital readmission rates.
- Sector
- Healthcare
- HQ
- Or Yehuda, Israel
- Founded
- 2015
- Employees
- 9
- Website
- restoremedical.co/
- Ownership
- Privately Held (backing)
Restore Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Restore Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Restore Medical in its N-PORT filings yet. We sweep new filings monthly.